Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

A study published earlier this week in Nature Communications using claims data from the US Veterans Affairs (VA) Healthcare ...

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Pfizer posts mixed first-quarter results, maintains annual forecast COVID vaccine sales better-than-expected, while sales of antiviral treatment decline Expects to save $7.7 billion in costs by ...

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

The unusual move at FDA comes shortly after the agency's longtime vaccine chief was forced out over disagreements with Makary ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable ...